Company Aptorum Group Limited

APM

KYG6096M1226

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Annual profits - Rate of surprise

Sector Other Pharmaceuticals

Delayed Nasdaq Other stock markets 09:32:39 2024-04-25 am EDT			5-day change	1st Jan Change
5.57 ^USD	+0.18%		+3.72%	+127.48%

Mar. 06	Top Midday Gainers	MT
Mar. 06	YOOV Group Holding Limited entered into a entered into an Agreement and Plan of Merger to acquire Aptorum Group Limited for $250 million in a reverse merger transaction.	CI

Aptorum Group Limited is United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company's business segments include Therapeutics and Non-Therapeutics. Therapeutics segment is engaged in developing various drug molecules and certain technologies for treatment of human disease conditions. Two of the Companyâs lead projects, ALS-4 and SACT-1, target infectious disease and cancer, including orphan oncology indications. Non-Therapeutics segment encompasses three businesses: diagnostics projects including PathsDx Test, natural supplements including NativusWell, and AML Clinic. PathsDx Test is a novel molecular-based rapid pathogen identification and detection diagnostics technology, which is under co-development with A*STAR.

Number of employees: 19

USD in Million	2021	Weight	2022	Weight	Delta
Healthcare Service 100.0 %	2	100.0 %	1	100.0 %	-15.95%

USD in Million	2021	Weight	2022	Weight	Delta
Hong Kong 100.0 %	2	100.0 %	1	100.0 %	-15.95%

Managers	Title	Age	Since
Ian Huen FOU	Founder	44	10-09-12
Martin Siu DFI	Director of Finance/CFO	-	22-06-30
Wai-Yip Lee CTO	Chief Tech/Sci/R&D Officer	51	19-03-31
Clark Cheng CTO	Chief Tech/Sci/R&D Officer	44	18-01-01

Members of the board	Title	Age	Since
Mirko Scherer BRD	Director/Board Member	55	17-09-30
Ian Huen FOU	Founder	44	10-09-12
Clark Cheng CTO	Chief Tech/Sci/R&D Officer	44	18-01-01
Justin Wu BRD	Director/Board Member	54	17-09-30
Charles Bathurst BRD	Director/Board Member	69	17-09-30
Douglas Arner BRD	Director/Board Member	54	18-03-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	2,243,776	0	0	38.85 %
Stock B	1	2,937,921	2,012,839 ( 68.51 %)	0

Name	Equities	%	Valuation
Darren Lui 13.67 %	401,537	13.67 %	4 M $
Ian Huen 12.60 %	370,308	12.60 %	4 M $
Geode Capital Management LLC 1.312 %	38,552	1.312 %	365 858 $
Morgan Stanley Capital Services LLC 0.1786 %	5,246	0.1786 %	49 785 $
NewEdge Advisors LLC 0.000034 %	1	0.000034 %	9 $
Hudson Bay Capital Management LP 0.000000 %	0	0.000000 %	- $

Name	Equities	%	Valuation
Ian Huen 7.158 %	1,606,147	7.158 %	15 M $

Aptorum Group Ltd.

17 Hanover Square

W1S 1BN, London

+44 20 8092 9299

http://www.aptorumgroup.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
APTORUM GROUP LIMITED	+127.48%	30.42M
NOVO NORDISK A/S	+24.14%	562B
JOHNSON & JOHNSON	-6.34%	358B
MERCK & CO., INC.	+19.68%	322B
ABBVIE INC.	+7.47%	297B
ASTRAZENECA PLC	+13.28%	219B
NOVARTIS AG	+6.22%	199B
ROCHE HOLDING AG	-10.59%	196B
PFIZER, INC.	-10.78%	149B
AMGEN INC.	-6.77%	146B

Other Pharmaceuticals